Cosmo N.V. (LON:0RGI)
London · Delayed Price · Currency is GBP · Price in CHF 76.10
+0.90 (1.20%)
May 13, 2026, 5:15 PM GMT
51.59% (1Y)
| Market Cap | 1.14B +67.2% |
| Revenue (ttm) | 90.88M -61.0% |
| Net Income | -3.15M |
| EPS | -0.20 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 1,071.22 |
| Dividend | 1.82 (2.45%) |
| Ex-Dividend Date | Apr 24, 2026 |
| Volume | 44,188 |
| Average Volume | 12,368 |
| Open | 76.00 |
| Previous Close | 75.20 |
| Day's Range | 73.70 - 79.50 |
| 52-Week Range | 49.60 - 129.60 |
| Beta | 1.48 |
| RSI | 32.21 |
| Earnings Date | Jul 20, 2026 |
About Cosmo
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral ... [Read more]
Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1997
Employees 325
Stock Exchange London Stock Exchange
Ticker Symbol 0RGI
News
Cosmo price target raised to CHF 160 from CHF 130 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Cosmo Pharmaceuticals (CMOPF) to CHF 160 from CHF 130 and keeps a Buy rating on the shares. The firm cites the addition…
23 days ago - TheFly